Skip to content
Accessibility help

Search NICE…

Skip to content

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
Skip More from NICE submenu
Explore more from NICE
What NICE does
About us
Reusing our content
Implementing NICE guidance
News, blogs and podcasts
Contact us
Get involved
Careers
- Join a committee
- Comment on a consultation

My account

Consultation responses
Sign in

You are here:

Home
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

Technology appraisal guidance
Reference number: TA193
Published: 28 July 2010

Guidance
Tools and resources
Information for the public
History

Appeal: Joint: Royal College of Pathologists and British Society for Haematology

Appeal received
Initial scrutiny letter
Response to initial scrutiny letter
Final scrutiny letter
Appraisal committee response
Response to appraisal comittee

This page was last updated: 21 May 2010

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS) Clinical Knowledge Summaries
British National Formulary (BNF) British National Formulary
British National Formulary for Children (BNFC) British National Formulary for Children
Life sciences
Library and knowledge services

What NICE does
Implementing NICE guidance
Get involved
About us
Careers
News, blogs and podcasts
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2025. All rights reserved. Subject to Notice of rights.